Lincocin is a medicine containing the active ingredient(s) lincomycin. On this page you will find out more about Lincocin, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: lincomycin
Information for medicine and pack size:
Lincocin 600 mg/2 mL injection solution, 5 x 2 mL vials
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INDICATIONS AS AT 22 SEPTEMBER 1994: LINCOCIN is indicated in the treatment of serious infections due to susceptible strains of gram positive aerobes such as streptococci, pneumococci and staphylococci. Its use should be reserved for penicillin allergic patients or other patients for whom, in the judgement of the physician, a penicillin is inappropriate. Because of the risk of colitis (see PRECAUTIONS), before selecting lincomycin the physician should consider the nature of infection and the suitability of less toxic alternatives (e.g.erythromycin). LINCOCIN has been demonstrated to be effective in the treatment of staphylococcal infections resistant to other antibiotics and susceptible to lincomycin. Staphylococcal strains resistant to LINCOCIN have been recovered; culture and susceptibility studies should be done in conjunction with LINCOCIN therapy. In the case of macrolides, partial but not complete cross resistance may occur. The drug may be administered concomitantly with other antimicrobial agents with which it is compatible when indicated (see PRECAUTIONS). The specific infections for which LINCOCIN is indicated are as follows: - Upper respiratory infections including tonsillitis, pharyngitis, otitis media, sinusitis, scarlet fever and as adjuvant therapy for diphtheria. Effectiveness in the treatment of mastoiditis would be anticipated. - Lower respiratory infections including acute and chronic bronchitis and pneumonia. - Skin and skin structure infections including cellulitis, furuncles, abscesses, impetigo, acne and wound infections. Conditions such as erysipelas, lymphadenitis, paronychia (panaritium), mastitis and cutaneous gangrene should, if caused by susceptible organisms, respond to lincomycin therapy. - Bone and joint infections including osteomyelitis and septic arthritis. - Septicaemia and endocarditis. Selected cases of septicaemia and/or endocarditis due to susceptible organisms have responded well to lincomycin. However, bactericidal drugs are often preferred for these infections. - Bacillary Dysentery. Although Shigella is resistant to lincomycin in vitro (MIC approximately 200 400 micrograms/mL), lincomycin has been effective in its treatment due to the very high levels of lincomycin attained in the bowel (approximately 3000 7000 micrograms/gram of stool).
Table of characteristics
|Visual appearance||Clear colourless liquid|
|Dosage Form||Injection, solution|
|Route of administration||Intravenous|
5 X 2mL: Prescription Only Medicine, or Prescription Animal Remedy
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 25 degrees Celsius|
|Storage conditions||Do not Freeze,Protect from Light|
|Life time||2 Years|
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 May 2018
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.